rivaroxaban bayer 15 mg tabletki powlekane
bayer ag - rivaroxabanum - tabletki powlekane - 15 mg
rivaroxaban bayer 20 mg tabletki powlekane
bayer ag - rivaroxabanum - tabletki powlekane - 20 mg
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - Środki do zapalenia skóry, z wyłączeniem kortykosteroidy - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
akvir o smaku truskawkowym 250 mg/5 ml syrop
zakłady farmaceutyczne polpharma s.a. - inosinum pranobexum - syrop - 250 mg/5 ml
akvir forte o smaku truskawkowym 500 mg/5 ml syrop
zakłady farmaceutyczne polpharma s.a. - inosinum pranobexum - syrop - 500 mg/5 ml
aripiprazole sandoz 10 mg tabletki ulegające rozpadowi w jamie ustnej
sandoz gmbh - aripiprazolum - tabletki ulegające rozpadowi w jamie ustnej - 10 mg
aripiprazole sandoz 15 mg tabletki ulegające rozpadowi w jamie ustnej
sandoz gmbh - aripiprazolum - tabletki ulegające rozpadowi w jamie ustnej - 15 mg
aripiprazole sandoz 30 mg tabletki ulegające rozpadowi w jamie ustnej
sandoz gmbh - aripiprazolum - tabletki ulegające rozpadowi w jamie ustnej - 30 mg
kivizidiale (40 mcg + 5 mg)/ml krople do oczu, roztwór
bausch+lomb ireland ltd. - travoprostum + timololi maleas - krople do oczu, roztwór - (40 mcg + 5 mg)/ml
fluenz tetra
astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - grypa, człowiek - szczepionki przeciw grypie, flu, żywa аттенуированная - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. stosowanie fluenz tetra powinno być oparte na oficjalnych zaleceniach.